RT Journal Article
SR Electronic
T1 Key performance indicators of COVID-19 contact tracing in Belgium from September 2020 to December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.04.22280542
DO 10.1101/2022.10.04.22280542
A1 Kremer, Cécile
A1 Willem, Lander
A1 Boone, Jorden
A1 Arrazola de Oñate, Wouter
A1 Hammami, Naïma
A1 Faes, Christel
A1 Hens, Niel
YR 2022
UL http://medrxiv.org/content/early/2022/10/06/2022.10.04.22280542.abstract
AB Background Contact tracing aims to prevent onward transmission of infectious diseases and data obtained during tracing provide unique information on transmission characteristics. A key performance indicator that has been proposed to evaluate contact tracing is the proportion of cases arising from known contacts. However, few empirical studies have investigated the effectiveness of contact tracing.Methods Using data collected between September 2020 and December 2021 in Belgium, we investigated the impact of contact tracing on SARS-CoV-2 transmission. We compared confirmed cases that were previously identified as a close contact to those that were not yet known, in terms of their traced contacts and secondary cases as well as the serial interval. In addition, we established contact and transmission patterns by age.Findings Previously traced, hence ‘known’, cases comprised 20% of all cases and they were linked to relatively fewer close contacts as well as fewer secondary cases and a lower secondary attack rate compared to cases that were not already known. In addition we observed a shorter serial interval for ‘known’ cases. There was a relative increase in transmission from children to adults during circulation of the Delta and Omicron variants, without an increase in the extent of contact between these age groups.Interpretation These results suggest that contact tracing in Belgium has been effective in reducing onward transmission and that individuals aware of their exposure to SARS-CoV-2 seemed more reserved in their social contact behaviour. Data from a reference period or region are needed to measure the impact of contact tracing in terms of the number of cases and deaths averted.Competing Interest StatementNaïma Hammami is an employee of the the Flemish Agency for Care and Health and Jorden Boone has been working as a consultant for the agency during the COVID-19 pandemic. Niel Hens declares that the Universities of Antwerp and Hasselt have received funding for advisory boards and research projects of MSD, GSK, JnJ, Pfizer outside the proposed work. Niel Hens has not received any personal remuneration related to this work. The other authors declare that they have no competing interests.Funding StatementPart of this project was funded by the Flemish Agency for Care and Health, which also provided the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Agency for Care and Health (GE0-1GDF2IAWT/1GD305/20069780). This project falls within the legal authorities of the Agency for Care and Health and therefore no explicit ethical decision is needed. The study was conducted in accordance with international ethical standards (Declaration of Helsinki 1964). The study was conducted in accordance to the General Data Protection Regulation (GDPR) and a data processing agreement between the Agency of Care and Health and the Universities of Antwerp and Hasselt was concluded. Participant information was coded and held securely. De-identification was performed on data content to comply with the Data Protection Regulation scope.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe line list data and R code will be made publicly available upon publication of the manuscript.